Publications

457 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

GVS advice on extension of List 2 reimbursement conditions of subcutaneous CGRP inhibitors

The National Health Care Institute assessed whether the reimbursement conditions of the subcutaneous CGRP inhibitors erenumab ...

Report | 11-07-2023
Package advice on the lock procedure medicinal product lenvatinib (Lenvima®) for the treatment of endometrial carcinoma

The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

Report | 06-07-2023
GVS advice avacopan (Tavneos®) for the treatment of certain patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

The National Health Care Institute has assessed whether avacopan (Tavneos®) can be included in the Medicine Reimbursement System ...

Report | 15-06-2023
GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults

The National Health Care Institute has assessed whether the hepatitis B vaccine PreHevbri® can be included in the Medicine ...

Report | 02-06-2023
GVS advice lasmiditan (Rayvow®) for the treatment of migraine

The National Health Care Institute has assessed whether lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System ...

Report | 23-05-2023
Advice on the clustering of combination products and ghost clusters in GVS (part 4)

The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

Report | 23-05-2023
Advice on the clustering of combination products and ghost clusters in GVS (part 3)

The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

Report | 23-05-2023
GVS advice dapagliflozin (Forxiga®) extension of List 2 conditions

The National Health Care Institute has assessed whether the reimbursement conditions for dapagliflozin (Forxiga®) can be ...

Report | 23-05-2023
Advice on the clustering of combination products and ghost clusters in GVS (part 2)

The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

Report | 23-05-2023
Package advice lenvatinib (Kisplix®) in combination with pembrolizumab for the treatment of renal cell carcinoma

The National Health Care Institute has assessed whether the medicinal product lenvatinib (Kisplix®) in combination with ...

Report | 15-05-2023

Publications

457 publications

GVS advice on extension of List 2 reimbursement conditions of subcutaneous CGRP inhibitors

Package advice on the lock procedure medicinal product lenvatinib (Lenvima®) for the treatment of endometrial carcinoma

GVS advice avacopan (Tavneos®) for the treatment of certain patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults

GVS advice lasmiditan (Rayvow®) for the treatment of migraine

Advice on the clustering of combination products and ghost clusters in GVS (part 4)

Advice on the clustering of combination products and ghost clusters in GVS (part 3)

GVS advice dapagliflozin (Forxiga®) extension of List 2 conditions

Advice on the clustering of combination products and ghost clusters in GVS (part 2)

Package advice lenvatinib (Kisplix®) in combination with pembrolizumab for the treatment of renal cell carcinoma

Go to